AXGNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Axogen, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$35.24+0.62 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $1.88B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$18.65 (+112.4%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Axogen, Inc. grew revenue 23.6% to $251.17M over the twelve months to Jun 30, 2026. Operating income fell 850.5% to -$12.85M, moving the operating margin from 0.8% to -5.1%. Free cash flow was $8.60M, up 74.0% from a year earlier.
Revenue
$251.17M
+23.6% vs. a year earlier
Operating income
-$12.85M
-850.5% vs. a year earlier
Free cash flow
$8.60M
+74.0% vs. a year earlier
EPS, diluted
-$0.68
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.88B
- P/E ratio
- –
- Price to sales
- 7.48
- Price to book
- 7.34
- Dividend yield
- –
- Free cash flow yield
- 0.46%
Fundamentals
- Revenue
- $251.17M
- Net income
- -$33.55M
- EPS, diluted
- -$0.68
- Free cash flow
- $8.60M
- Book value per share
- $4.80
- Diluted shares
- 53M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$251.17M+23.6% YoY
Gross profit
$187.27M+24.0% YoY
Operating income
-$12.85M-850.5% YoY
Net income
-$33.55M
EPS, diluted
-$0.68
Free cash flow
$8.60M+74.0% YoY
Reported periodTrailing twelve months